{
    "clinical_study": {
        "@rank": "112780", 
        "arm_group": {
            "arm_group_label": "Single arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, Phase 1/2 study.  The study will evaluate the tolerability, safety\n      and activity of AMG 337 in Asian subjects who have advanced solid tumors (Phase 1) or\n      subjects with MET amplified tumors with a focus on gastric/gastroesophageal\n      junction/esophageal adenocarcinoma (Phase 2)."
        }, 
        "brief_title": "A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Stomach Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1/2, multicenter, single arm, open-label study to assess the safety,\n      efficacy and pharmacokinetics of AMG 337 in solid tumors.  In the Phase 1, approximately 3\n      to 27 subjects enrolled in a 3+3+3 dose escalation scheme evaluating two dose levels.  In\n      the Phase 2, approximately 140 subjects will be enrolled to either Cohort 1 (subjects with\n      MET amplified /gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma with measurable\n      tumor) or Cohort 2 (subjects with MET amplified solid tumors with measurable tumor and\n      subjects with MET amplified G/GEJ/E adenocarcinoma with non-measurable tumor).  All subjects\n      will sel-administer AMG 337 daily until disease progression or other protocol specified end\n      of treatment criteria are met.  Tumor assessment by RECIST 1.1 will be followed during study\n      treatment.\n\n      Tumor tissue, biomarkers, pharmacokinetics and Patient Reported Outcomes will be assessed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to self administer daily AMG 337 as a whole capsule\n\n          -  Male or female 20 years of age or over\n\n          -  Phase 1: Subjects must have a pathologically confirmed, advanced solid tumor for\n             which the subjects have received prior therapy for advanced disease, for which no\n             standard therapy exists, or the subject refuses standard therapy.\n\n          -  Phase 2: Subjects must have a pathologically confirmed, advanced G/GEJ/E\n             adenocarcinoma (cohort 1) or other solid tumor (cohort 2) for which the subjects have\n             received prior therapy for advanced disease, or for which no standard therapy exists,\n             or the subject refuses standard therapy.\n\n          -  Tumor MET amplified by protocol-specified centralized testing (phase 2 only).\n\n          -  Phase 1: Measurable or non-measurable disease per RECIST v1.1\n\n          -  Phase 2: Measurable disease per RECIST v1.1 guidelines. Cohort 2 may include\n             subjects with advanced MET amplified G/GEJ/E adenocarcinoma with non-measurable tumor\n             per RECIST v1.1.\n\n          -  (ECOG) Performance Status of 0 or 1\n\n          -  Other protocol defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Known central nervous system metastases.\n\n          -  Subject is a candidate for curative surgery or definitive chemoradiation.\n\n          -  Peripheral edema > grade 1.\n\n          -  Subjects who have persistent gastric outlet obstruction, complete dysphagia or are\n             dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that\n             in the opinion of the Investigator may influence drug absorption.\n\n          -  Currently receiving any anti-tumor treatments, or less than 14 days prior to\n             enrollment since ending anti-tumor treatment.\n\n          -  Prior treatment with small molecule inhibitors of the MET pathway.\n\n          -  Other protocol defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "149", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096666", 
            "org_study_id": "20120370"
        }, 
        "intervention": {
            "arm_group_label": "Single arm", 
            "description": "Phase 1- AMG 337 150 mg and 300 mg orally daily.  Phase 2- AMG 337 (dose determined by Phase 1) orally daily.", 
            "intervention_name": "AMG 337", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "MET Amplified Gastric/ Gastroesophageal Junction/ Esophageal Adenocarcinomas, or other solid tumors", 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-shi", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "277-8577"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suntou-gun", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "411-8777"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects", 
        "other_outcome": [
            {
                "description": "Evaluate tumor MET amplification and expression, expression levels and mutations of genes relevant to MET signaling, serum cytokine levels, circulating HGF, soluble MET, MET amplification in serum and circulating tumor cell analysis.", 
                "measure": "Phase 1- Biomarker Evaluation", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "description": "To evaluate the impact of AMG 337 on health-related quality of life (HRQoL) in subjects with measurable MET amplified Gastric/Gastroesophageal junction/Esophageal adenocarcinoma (cohort 1)", 
                "measure": "Phase 2- Patient Reported Outcomes (PRO) Health related quality of life (HRQoL)", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "description": "Circulating tumor cells and circulating biomarkers will be assessed at baseline and during study treatment.", 
                "measure": "Tumor tissue and circulating serum biomarkers", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "description": "To analyze tumor DNA samples for MET pathway-related genes (and other genes based on emerging data) that may predict response to AMG 337.", 
                "measure": "Prediction of response rates to AMG 337 by analyzing tumor DNA for MET pathway-related genes", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "description": "Explore whether the level of MET amplification, expression, or presence of mutation in tumor specimens correlates with response to AMG 337.", 
                "measure": "Response to AMG 337 and MET amplification, expression or presence of mutation in tumor specimens", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }
        ], 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Japan: Ministry of Health, Labor and Welfare", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events and clinical laboratory abnormalities defined as DLTs.", 
                "measure": "Phase 1- Adverse events and clinical laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "17 months"
            }, 
            {
                "description": "Determine anti-tumor activity of AMG 337 in subjects with MET amplified gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1)", 
                "measure": "Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with MET amplified measurable gastric/gastroesophageal junction/esophageal adenocarcinoma (cohort 1)", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Including, but not limited to, minimum (trough) concentrations, maximum concentrations (C max), the time of C max (t max), and area under the plasma concentration- time curve (AUC).", 
                "measure": "Phase 1- Pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "17 months"
            }, 
            {
                "measure": "Phase 1- Other adverse events, clinical laboratory abnormalities and ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "17 months"
            }, 
            {
                "description": "Determine anti-tumor activity in AMG 337 in subjects with MET amplified solid tumors (subjects with measurable disease in cohort 2)", 
                "measure": "Phase 2- Overall Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2)", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "measure": "Phase 2- Duration of Response (cohort 1 and subjects with measurable disease at baseline in cohort 2)", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "measure": "Phase 2- Time to response (cohort 1 and subjects with measurable disease at baseline in cohort 2)", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "measure": "Phase 2- Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "measure": "Phase 2- Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "17 months"
            }, 
            {
                "measure": "Phase 2- Incidence and severity of adverse events and significant laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "17 months"
            }, 
            {
                "measure": "Phase 2- AMG 337 exposure and dose intensity", 
                "safety_issue": "Yes", 
                "time_frame": "17 months"
            }, 
            {
                "description": "Including, but not limited to, minimum (trough) concentrations at pre-dose times and maximum concentrations (C max), the time of C max (t max), and area under the plasma concentration- time curve (AUC) for intensive pharmacokinetic sampling.", 
                "measure": "Phase 2- Pharmacokinetic parameters", 
                "safety_issue": "Yes", 
                "time_frame": "17 months"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}